• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

EBAG9 recombinant protein

Scan QR to view Datasheet
Catalog # MBS203246
Unit / Price
  0.1 mg  /  $255 +1 FREE 8GB USB
  0.5 mg  /  $535 +1 FREE 8GB USB
Product Name

EBAG9, Recombinant Protein

Also Known As

EBAG9, 28-213aa, Human,His tag, E Coli

Product Synonym Names
Estrogen receptor binding site associated antigen 9; EB9; PDAF; RCAS1; Estrogen receptor binding site associated antigen 9; EBAG9; Estrogen receptor binding site associated; antigen 9 BAG9; Cancer associated surface antigen; Cancer associated surface antigen RCAS1; EBAG 9; Estrogen receptor binding fragment associated gene 9 protein; PDAF; RCAS 1; RCAS1; Receptor binding cancer antigen expressed on SiSo cells.
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Sequence Length
AF006265 mRNA
3D Structure
ModBase 3D Structure for O00559
E Coli
> 90% by SDS PAGE
Liquid in 20 mM Tris pH 8.0, 1 mM DTT, 2 mM EDTA, 10% glycerol
1 mg/ml (determined by Bradford assay) (lot specific)
Antigen Species
Tag Information
Preparation and Storage
Can be stored at 4 degree C short term (1-2 weeks).
For long term storage, aliquot and store at -20 degree C or -70 degree C.
Avoid repeated freezing and thawing cycles.
Other Notes
Small volumes of EBAG9 recombinant protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
EBAG9 recombinant protein
Estrogen receptor binding site associated antigen 9, also known as EBAG9, is a type III transmembrane protein that is predominantly located in the Golgi. This protein is a tumor-associated antigen that is expressed at high frequency in a variety of cancers, such as advanced breast and prostate cancers. As the EBAG9 acts to inhibit the growth of receptor-binding cells and induced apoptosis of immune cells, cancer cells might evade immune surveillance. So immunodetection of EBAG9 expression can be a negative prognostic indicator. Recombinant human EBAG9 protein, fused to His-tag at N-terminus, was expressed in E Coli and purified by using conventional chromatography techniques.
Product Categories/Family for EBAG9 recombinant protein
Applications Tested/Suitable for EBAG9 recombinant protein

NCBI/Uniprot data below describe general gene information for EBAG9. It may not necessarily be applicable to this product.
NCBI Accession #
NCBI GenBank Nucleotide #
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
23.4 kDa (207 aa), confirmed by MALDI-TOF. (Molecular weight on SDS-PAGE will appear higher)
NCBI Official Full Name
receptor-binding cancer antigen expressed on SiSo cells
NCBI Official Synonym Full Names
estrogen receptor binding site associated, antigen, 9
NCBI Official Symbol
EBAG9  [Similar Products]
NCBI Official Synonym Symbols
  [Similar Products]
NCBI Protein Information
receptor-binding cancer antigen expressed on SiSo cells
UniProt Protein Name
Receptor-binding cancer antigen expressed on SiSo cells
UniProt Synonym Protein Names
Cancer-associated surface antigen RCAS1; Estrogen receptor-binding fragment-associated gene 9 protein
UniProt Gene Name
EBAG9  [Similar Products]
UniProt Synonym Gene Names
RCAS1  [Similar Products]
NCBI Summary for EBAG9
This gene was identified as an estrogen-responsive gene. Regulation of transcription by estrogen is mediated by estrogen receptor, which binds to the estrogen-responsive element found in the 5'-flanking region of this gene. The encoded protein is a tumor-associated antigen that is expressed at high frequency in a variety of cancers. Alternate splicing results in multiple transcript variants. A pseudogene of this gene has been defined on chromosome 10. [provided by RefSeq, Jul 2013]
UniProt Comments for EBAG9
May participate in suppression of cell proliferation and induces apoptotic cell death through activation of interleukin-1-beta converting enzyme (ICE)-like proteases.
Product References and Citations for EBAG9 recombinant protein
Kumagai J., et al., (2009) Int J Cancer.124 (4):816-26.; Yoshida S., et al., (2008) J Rheumatol. 35 (9):1716-22.;

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated withEBAG9 recombinant protein
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

Contact Us

Please fill out the form below and our representative will get back to you shortly.